FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the Ministry of Commerce of the People’s Republic of China (MOFCOM) for BD to acquire C. R. Bard (NYSE: BCR), contingent on BD divesting its soft... Read more
COLUMBUS, Neb., Oct. 25, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to break ground on a $60 million upgrade of its Columbus-East facility. The 69,000 sq. ft. expansion will transform the Columbus-East facility into... Read more
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line: “We continue to make... Read more
FRANKLIN LAKES, N.J., Sept. 29, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that two current directors of C.R. Bard, Inc. will join the BD board of directors following the completion of BD’s pending acquisition of Bard. Timothy M. Ring, chairman and CEO of Bard,... Read more
FRANKLIN LAKES, N.J., Sept. 26, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test... Read more
FRANKLIN LAKES, N.J. and SIZIANO, Italy, Sept. 20, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Euroclone (Euroclone Diagnostica Srl) today announced a development and global distribution agreement for molecular tests to detect emerging sexually-transmitted pathogens. According to the World Health Organization, more than 1 million... Read more
FRANKLIN LAKES, N.J., Sept. 12, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to detect rare molecules responsible for biological diversity that are often missed with whole transcriptome profiling. Developed using the company’s... Read more
FRANKLIN LAKES, N.J., Sept. 8, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2017 on Tuesday, September 12, 2017, at 9:10 a.m. EDT. A live webcast of BD’s presentation can be accessed from the BD... Read more
MURRAY HILL, N.J. and FRANKLIN LAKES, N.J., Aug. 8, 2017 /PRNewswire/ — C. R. Bard, Inc. (NYSE: BCR) (“Bard”) and Becton, Dickinson and Company (NYSE: BDX) (“BD”) today announced the results of Bard’s special meeting of shareholders, held on August 8, 2017 and at which a quorum was present, for Bard shareholders to consider and vote... Read more
BD FACSLyric™ Flow Cytometer System with BD Multitest™ Assays Offers Reliability and Consistency Jul 19, 2017 FRANKLIN LAKES, N.J., July 19, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™... Read more